Getinge AB (publ) (BIT:1GETI)
Italy · Delayed Price · Currency is EUR | Market Cap | 6.40B +24.3% |
| Revenue (ttm) | 3.09B -3.6% |
| Net Income | 241.67M +79.6% |
| EPS | 0.89 +79.6% |
| Shares Out | n/a |
| PE Ratio | 26.46 |
| Forward PE | 19.22 |
| Dividend | 0.44 (2.02%) |
| Ex-Dividend Date | Apr 22, 2026 |
| Volume | n/a |
| Open | 21.82 |
| Previous Close | 21.82 |
| Day's Range | 21.82 - 21.82 |
| 52-Week Range | 16.49 - 22.59 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Getinge AB
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardioth... [Read more]
Financial Performance
In 2025, Getinge AB's revenue was 34.97 billion, an increase of 0.60% compared to the previous year's 34.76 billion. Earnings were 2.26 billion, an increase of 37.85%.
Financial numbers in SEK Financial StatementsNews
Getinge downgraded to Hold from Buy at Pareto
Pareto analyst Christian Lee downgraded Getinge (GNGBY) to Hold from Buy with an unchanged price target of SEK 255. The firm cites the company’s tough compares for the downgrade. Published…
Getinge AB Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Operational improvements and a long-term cultural shift have driven margin gains and compliance. EMEA and U.S. markets remain strong, while China stabilizes. Product innovation, especially in acute care and life science, supports growth, with Paragonix integration and M&A flexibility enhancing strategic options.
Getinge initiated with a Neutral at UBS
UBS initiated coverage of Getinge (GNGBY) with a Neutral rating and SEK 255 price target The stock’s current valuation already reflects its portfolio mix shift and stronger growth outlook. Published…
Getinge downgraded to Hold from Buy at Nordea
Nordea downgraded Getinge (GNGBY) to Hold from Buy.
Getinge AB Earnings Call Transcript: Q2 2026
Q2 2026 saw robust organic growth in sales and orders, margin expansion aided by a tariff refund, and strong cash flow. High-margin and recurring revenues increased, while guidance for 2026 organic net sales growth of 3%-5% was reiterated amid ongoing geopolitical and supply chain challenges.
Getinge AB Quarterly report: Q2 2026
Getinge AB has published its Q2 2026 quarterly earnings report on July 17, 2026.
Getinge AB Slides: Q2 2026
Getinge AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 17, 2026.
Getinge maintains FY26 organic sales growth view of 3%-5%
There is currently high geopolitical uncertainty, however, based on dialogue with its customers Getinge (GNGBY) is maintaining the forecast of organic sales growth of 3-5% in 2026. Published first on…
Getinge AB Earnings Call Transcript: Q1 2026
Organic net sales grew 0.8% year-over-year, with strong order intake and solid cash flow despite SEK 226 million in tariff and currency headwinds. Life Science and Surgical Workflows led growth, while guidance for 2026 organic net sales growth of 3%-5% was reiterated.
Getinge AB Quarterly report: Q1 2026
Getinge AB has published its Q1 2026 quarterly earnings report on April 21, 2026.
Getinge AB Slides: Q1 2026
Getinge AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.
Getinge AB Earnings Call Transcript: Q4 2025
Record organic sales growth in Q4 2025 was driven by strong performance in Acute Care Therapies and Surgical Workflows, while Life Science lagged. Margin expansion remains a focus for 2026 despite ongoing tariff and FX headwinds, with 3%-5% organic net sales growth guided.
Getinge AB Annual report: Q4 2025
Getinge AB has published its Q4 2025 annual report on January 27, 2026.
Getinge AB Quarterly report: Q4 2025
Getinge AB has published its Q4 2025 quarterly earnings report on January 27, 2026.
Getinge AB Slides: Q4 2025
Getinge AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 27, 2026.
Getinge upgraded to Buy from Hold at Nordea
Nordea analyst Ludvig Lundgren upgraded Getinge (GNGBY) to Buy from Hold with a SEK 245 price target
Getinge downgraded to Hold from Buy at Pareto
Pareto downgraded Getinge (GNGBY) to Hold from Buy with a SEK 245 price target
Getinge AB Earnings Call Transcript: Q3 2025
Strong organic growth and margin improvement in Q3, led by ACT and Life Science, offset tariff and FX headwinds. Solid financial position and guidance for 2%-5% organic net sales growth in 2025 are maintained, with ongoing focus on quality, productivity, and cost control.
Getinge AB Quarterly report: Q3 2025
Getinge AB has published its Q3 2025 quarterly earnings report on October 21, 2025.
Getinge AB Slides: Q3 2025
Getinge AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 21, 2025.
Medical gear maker Getinge tops core profit estimates in third quarter
Swedish medical equipment maker Getinge reported third-quarter core earnings above market expectations on Tuesday, supported by price adjustments to combat a hit from U.S. tariffs and negative currenc...
Getinge price target lowered to SEK 175 from SEK 182 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Getinge (GNGBY) to SEK 175 from SEK 182 and keeps an Equal Weight rating on the shares.
Getinge price target lowered to SEK 165 from SEK 191 at JPMorgan
JPMorgan lowered the firm’s price target on Getinge (GNGBY) to SEK 165 from SEK 191 and keeps an Underweight rating on the shares.
Getinge AB Earnings Call Transcript: Q2 2025
Solid organic growth and margin improvement achieved despite significant tariff and FX headwinds, with strong performance in Acute Care Therapies and Surgical Workflows. Financial position remains robust, and 2025 guidance for 2–5% organic net sales growth is reaffirmed.
Getinge AB Quarterly report: Q2 2025
Getinge AB has published its Q2 2025 quarterly earnings report on July 18, 2025.